Business
FluoroPharma Medical Announces Details for Investor Call on January 6th
FluoroPharma Medical Announces Details for Investor Call on January 6th.
About this update from Fluoropharma Medical Inc
[{"type":"text","content":"\n\n FluoroPharma Medical Announces Details for Investor Call on January 6th\n \n\nFluoroPharma Medical Announces Details for Investor Call on January 6th\n\n\n MONTCLAIR, NJ--(Marketwired - January 05, 2016) - FluoroPharma Medical Inc., (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:00 p.m. EST on Wednesday, January 6, 2016. The objectives of the call are to introduce Thomas H. Tulip, Ph.D., the company's new President and Chief Executive Officer, share his vision for the company, and address questions from investors. Questions may be submitted prior to the call by posting to [email protected]. Participants who would like to ask questions during the question and answer session must participate by telephone. Participants are encouraged to dial-in fifteen minutes before the conference call begins. Investors and the public are invited to access the live audio cast:\n Event: FluoroPharma Medical, Inc. Management Introduction\n Date and Time: Wednesday, January 6th, 4:00 PM ESTLive participant dial-in (Toll-free US and Canada): 877-407-8129Live participant dial-in (International): 201-493-6710The audio replay will be available until January 20, 2016:Replay dial-in (Toll-free US and Canada): 877-660-6853Replay dial-in (International): 201-612-7415\n About FluoroPharma Medical\n FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes. FluoroPharma's initial focus is the development of breakthrough PET imaging agents and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. Other active programs include the development of agents that could potentially be used for imaging specific cancers. In addition to the United States, Europe and China,...